NKTR vs. JPM
Compare and contrast key facts about Nektar Therapeutics (NKTR) and JPMorgan Chase & Co. (JPM).
Performance
NKTR vs. JPM - Performance Comparison
Loading graphics...
NKTR vs. JPM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NKTR Nektar Therapeutics | 79.07% | 203.08% | 64.60% | -75.00% | -83.27% | -20.53% | -21.26% | -34.32% | -44.96% | 386.72% |
JPM JPMorgan Chase & Co. | -7.92% | 37.27% | 44.29% | 30.63% | -12.64% | 27.75% | -5.53% | 47.26% | -6.62% | 26.76% |
Fundamentals
NKTR:
$1.54B
JPM:
$825.20B
NKTR:
-$10.15
JPM:
$20.42
NKTR:
22.15
JPM:
3.22
NKTR:
17.11
JPM:
2.41
NKTR:
$55.23M
JPM:
$256.52B
NKTR:
$55.04M
JPM:
$168.20B
NKTR:
-$122.97M
JPM:
$78.84B
Returns By Period
In the year-to-date period, NKTR achieves a 79.07% return, which is significantly higher than JPM's -7.92% return. Over the past 10 years, NKTR has underperformed JPM with an annualized return of -9.98%, while JPM has yielded a comparatively higher 20.50% annualized return.
NKTR
- 1D
- 5.23%
- 1M
- 10.75%
- YTD
- 79.07%
- 6M
- 28.65%
- 1Y
- 691.99%
- 3Y*
- 92.93%
- 5Y*
- -24.37%
- 10Y*
- -9.98%
JPM
- 1D
- 0.41%
- 1M
- -0.73%
- YTD
- -7.92%
- 6M
- -4.04%
- 1Y
- 23.71%
- 3Y*
- 34.51%
- 5Y*
- 16.89%
- 10Y*
- 20.50%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NKTR vs. JPM — Risk / Return Rank
NKTR
JPM
NKTR vs. JPM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and JPMorgan Chase & Co. (JPM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NKTR | JPM | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.69 | 0.94 | +2.75 |
Sortino ratioReturn per unit of downside risk | 5.91 | 1.34 | +4.57 |
Omega ratioGain probability vs. loss probability | 1.67 | 1.19 | +0.48 |
Calmar ratioReturn relative to maximum drawdown | 13.80 | 1.48 | +12.32 |
Martin ratioReturn relative to average drawdown | 33.65 | 4.00 | +29.65 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| NKTR | JPM | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.69 | 0.94 | +2.75 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.20 | 0.70 | -0.90 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.10 | 0.75 | -0.85 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.01 | 0.34 | -0.33 |
Correlation
The correlation between NKTR and JPM is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
NKTR vs. JPM - Dividend Comparison
NKTR has not paid dividends to shareholders, while JPM's dividend yield for the trailing twelve months is around 1.96%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NKTR Nektar Therapeutics | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
JPM JPMorgan Chase & Co. | 1.96% | 1.72% | 1.92% | 2.38% | 2.98% | 2.34% | 2.83% | 2.37% | 2.54% | 1.91% | 2.13% | 2.54% |
Drawdowns
NKTR vs. JPM - Drawdown Comparison
The maximum NKTR drawdown since its inception was -99.61%, which is greater than JPM's maximum drawdown of -76.16%. Use the drawdown chart below to compare losses from any high point for NKTR and JPM.
Loading graphics...
Drawdown Indicators
| NKTR | JPM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.61% | -76.16% | -23.45% |
Max Drawdown (1Y)Largest decline over 1 year | -46.54% | -15.47% | -31.07% |
Max Drawdown (5Y)Largest decline over 5 years | -97.93% | -38.77% | -59.16% |
Max Drawdown (10Y)Largest decline over 10 years | -99.61% | -43.63% | -55.98% |
Current DrawdownCurrent decline from peak | -95.35% | -11.72% | -83.63% |
Average DrawdownAverage peak-to-trough decline | -68.17% | -17.66% | -50.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.09% | 5.72% | +13.37% |
Volatility
NKTR vs. JPM - Volatility Comparison
Nektar Therapeutics (NKTR) has a higher volatility of 17.64% compared to JPMorgan Chase & Co. (JPM) at 6.28%. This indicates that NKTR's price experiences larger fluctuations and is considered to be riskier than JPM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| NKTR | JPM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.64% | 6.28% | +11.36% |
Volatility (6M)Calculated over the trailing 6-month period | 65.68% | 17.19% | +48.49% |
Volatility (1Y)Calculated over the trailing 1-year period | 189.39% | 25.24% | +164.15% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 121.48% | 24.34% | +97.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 96.96% | 27.38% | +69.58% |
Financials
NKTR vs. JPM - Financials Comparison
This section allows you to compare key financial metrics between Nektar Therapeutics and JPMorgan Chase & Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities